Difference between revisions of "Teniposide (Vumon)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
m |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Topoisomerase II inhibitor. Teniposide inhibits type II topoisomerase, which results in single and double-stranded DNA breaks and DNA-protein crosslinks. It is cell-cycle specific, acting in late S or early G2, preventing cells from entering mitosis. It is dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.<ref name="insert">[http://packageinserts.bms.com/pi/pi_vumon.pdf Teniposide (Vumon) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/teniposide.pdf Teniposide (Vumon) package insert (locally hosted backup)]</ref> | Class/mechanism: Topoisomerase II inhibitor. Teniposide inhibits type II topoisomerase, which results in single and double-stranded DNA breaks and DNA-protein crosslinks. It is cell-cycle specific, acting in late S or early G2, preventing cells from entering mitosis. It is dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.<ref name="insert">[http://packageinserts.bms.com/pi/pi_vumon.pdf Teniposide (Vumon) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/teniposide.pdf Teniposide (Vumon) package insert (locally hosted backup)]</ref> | ||
| Line 11: | Line 9: | ||
*[[B-cell acute lymphoblastic leukemia]] | *[[B-cell acute lymphoblastic leukemia]] | ||
*[[Burkitt lymphoma]] | *[[Burkitt lymphoma]] | ||
| − | |||
*[[HIV-associated lymphoma]] | *[[HIV-associated lymphoma]] | ||
| + | *[[Low-grade glioma]] | ||
*[[Small cell lung cancer]] | *[[Small cell lung cancer]] | ||
| + | |||
| + | ==Diseases for which it was used== | ||
| + | *[[Follicular lymphoma - obsolete |Follicular lymphoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://chemocare.com/bio/teniposide.asp Teniposide (Vumon) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/teniposide.asp Teniposide (Vumon) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/teniposide.asp Teniposide (Vumon) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/teniposide.asp Teniposide (Vumon) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/teniposide-patient-drug-information Teniposide (Vumon) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/teniposide-patient-drug-information Teniposide (Vumon) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/teniposide-patient-drug-information Teniposide (Vumon) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/teniposide-patient-drug-information Teniposide (Vumon) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' VM-26 | ||
| + | *'''Brand name:''' Vumon | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| Line 26: | Line 31: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| Line 34: | Line 38: | ||
[[Category:B-cell acute lymphoblastic leukemia medications]] | [[Category:B-cell acute lymphoblastic leukemia medications]] | ||
[[Category:Burkitt lymphoma medications]] | [[Category:Burkitt lymphoma medications]] | ||
| − | |||
[[Category:HIV-associated lymphoma medications]] | [[Category:HIV-associated lymphoma medications]] | ||
| + | [[Category:Low-grade glioma medications]] | ||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
[[Category:Drugs FDA approved in 1992]] | [[Category:Drugs FDA approved in 1992]] | ||
Revision as of 16:09, 20 January 2018
General information
Class/mechanism: Topoisomerase II inhibitor. Teniposide inhibits type II topoisomerase, which results in single and double-stranded DNA breaks and DNA-protein crosslinks. It is cell-cycle specific, acting in late S or early G2, preventing cells from entering mitosis. It is dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- B-cell acute lymphoblastic leukemia
- Burkitt lymphoma
- HIV-associated lymphoma
- Low-grade glioma
- Small cell lung cancer
Diseases for which it was used
Patient drug information
- Teniposide (Vumon) patient drug information (Chemocare)[3]
- Teniposide (Vumon) patient drug information (UpToDate)[4]
Also known as
- Code name: VM-26
- Brand name: Vumon
History of changes in FDA indication
- 7/14/1992: Initial FDA approval